Literature DB >> 33493427

Hydroxypropyl Cyclodextrin Improves Amiodarone-induced Aberrant Lipid Homeostasis of Alveolar Cells.

Shuhei Kanagaki1,2, Takahiro Suezawa1,2, Keita Moriguchi1,2, Kazuhisa Nakao2, Masayasu Toyomoto1,3, Yuki Yamamoto1, Koji Murakami2, Masatoshi Hagiwara3, Shimpei Gotoh1.   

Abstract

Alveolar epithelial type II (AT2) cells secrete pulmonary surfactant via lamellar bodies (LBs). Abnormalities in LBs are associated with pulmonary disorders, including fibrosis. However, high-content screening (HCS) for LB abnormalities is limited by the lack of understanding of AT2 cell functions. In the present study, we have developed LB cells harboring LB-like organelles that secrete surfactant proteins. These cells were more similar to AT2 cells than to parental A549 cells. LB cells recapitulated amiodarone (AMD)-induced LB enlargement, similar to AT2 cells of patients exposed to AMD. To reverse AMD-induced LB abnormalities, we performed HCS of approved drugs and identified 2-hydroxypropyl-β-cyclodextrin (HPβCD), a cyclic oligosaccharide, as a potential therapeutic agent. A transcriptome analysis revealed that HPβCD modulates lipid homeostasis. In addition, HPβCD inhibited AMD-induced LB abnormalities in human induced pluripotent stem cell-derived AT2 cells. Our results demonstrate that LB cells are useful for HCS and suggest that HPβCD is a candidate therapeutic agent for AMD-induced interstitial pneumonia.

Entities:  

Keywords:  2-hydroxypropyl-β-cyclodextrin; alveolar epithelial type 2 cells; amiodarone; high-content screening; lamellar bodies

Mesh:

Substances:

Year:  2021        PMID: 33493427     DOI: 10.1165/rcmb.2020-0119OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  4 in total

1.  Repurposing A549 Adenocarcinoma Cells: New Options for Drug Discovery.

Authors:  Carolina Garcia-de-Alba
Journal:  Am J Respir Cell Mol Biol       Date:  2021-04       Impact factor: 6.914

Review 2.  Perspectives of future lung toxicology studies using human pluripotent stem cells.

Authors:  Atsushi Masui; Toyohiro Hirai; Shimpei Gotoh
Journal:  Arch Toxicol       Date:  2022-01-01       Impact factor: 5.153

3.  Modeling of lung phenotype of Hermansky-Pudlak syndrome type I using patient-specific iPSCs.

Authors:  Takahiro Suezawa; Shuhei Kanagaki; Yohei Korogi; Kazuhisa Nakao; Toyohiro Hirai; Koji Murakami; Masatoshi Hagiwara; Shimpei Gotoh
Journal:  Respir Res       Date:  2021-11-04

4.  Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids.

Authors:  Takahiro Suezawa; Shuhei Kanagaki; Keita Moriguchi; Atsushi Masui; Kazuhisa Nakao; Masayasu Toyomoto; Koji Tamai; Ryuta Mikawa; Toyohiro Hirai; Koji Murakami; Masatoshi Hagiwara; Shimpei Gotoh
Journal:  Stem Cell Reports       Date:  2021-11-18       Impact factor: 7.765

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.